{"disease":{"id":"second-line-therapy","name":"second line therapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05074589","title":"Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06662877","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":206,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06892431","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT04713059","title":"Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)","phase":"","overall_status":"UNKNOWN","enrollment_count":62,"lead_sponsor_name":"The Affiliated Hospital of Qingdao University","has_results":false},{"nct_id":"NCT05927857","title":"Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT05722977","title":"Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07320586","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Shandong Tumor Hospital","has_results":false},{"nct_id":"NCT07530445","title":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07343453","title":"A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Sun Yat-sen University","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}